Friday, 16 October 2026European Markets

SIPEF And LUCASBOLS Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(VIANEWS) - SIPEF (SIP.BR) is among this list of stock assets with the highest dividend rate and return on equity on the Consumer Defensive sector.

Financial Asset Price Forward Dividend Yield Return on Equity
SIPEF (SIP.BR) €59.90 5.1% 13.91%
LUCASBOLS (BOLS.AS) €10.15 1.96% 5.57%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SIPEF (SIP.BR)

5.1% Forward Dividend Yield and 13.91% Return On Equity

Sipef NV operates as an agro-industrial company. It operates through Palm, Rubber, Tea, and Bananas and Plants segments. The company offers crude palm oil, palm kernels, and palm kernel oil; ribbed smoked sheets, and scraps and lumps; cut, tear, and curl tea; and bananas and plants from Ivory Coast. It has operations in Indonesia, Papua New Guinea, Ivory Coast, Singapore, Europe, and internationally. The company was incorporated in 1919 and is headquartered in Schoten, Belgium.

Earnings Per Share

As for profitability, SIPEF has a trailing twelve months EPS of €9.67.

PE Ratio

SIPEF has a trailing twelve months price to earnings ratio of 6.19. Meaning, the purchaser of the share is investing €6.19 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.91%.

Volatility

SIPEF's last week, last month's, and last quarter's current intraday variation average was 1.25%, 0.10%, and 0.94%.

SIPEF's highest amplitude of average volatility was 1.25% (last week), 0.95% (last month), and 0.94% (last quarter).

More news about SIPEF.

2. LUCASBOLS (BOLS.AS)

1.96% Forward Dividend Yield and 5.57% Return On Equity

Lucas Bols N.V. produces, bottles, markets, distributes, and sells cocktail and spirits. The company offers a range of spirits products, including liqueurs, genever, gin, and vodka under the Bols, Galliano, Passoã, Bokma, Bols Genevers, Coebergh, Damrak, Hartevelt, Henkes, Hoppe, KLM houses, Nuvo, Pallini, Pisang Ambon, Tequila Partida, Vaccari, Wynand Fockink, and Zwarte Kip brands. It operates in approximately 110 countries worldwide. Lucas Bols N.V. was formerly known as Lucas Bols Holding B.V. The company was founded in 1575 and is headquartered in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, LUCASBOLS has a trailing twelve months EPS of €0.8.

PE Ratio

LUCASBOLS has a trailing twelve months price to earnings ratio of 12.69. Meaning, the purchaser of the share is investing €12.69 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.57%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 23.4%, now sitting on 102.69M for the twelve trailing months.

Volume

Today's last reported volume for LUCASBOLS is 1547 which is 78.62% below its average volume of 7236.

Moving Average

LUCASBOLS's worth is below its 50-day moving average of €11.02 and below its 200-day moving average of €10.52.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, LUCASBOLS's stock is considered to be overbought (>=80).

More news about LUCASBOLS.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com